Company: BDRX
Filing Date: 2025-01-28
Form Type: 424B3
Source: 0001214659-25-001409
Chunk: 123

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-28
Form: 424B3
Chunk 123
---
below are unaudited and represent management’s estimate. The information in this table should be read in conjunction with and is
qualified by reference to the financial statements and notes thereto and other financial information contained in this prospectus.

| (£ in thousands)          |     | As of June 30, 2024 |       |     |                       |        |
|:--------------------------|:----|:--------------------|------:|:----|:----------------------|-------:|
|                           |     | Actual              |       |     | Pro Forma As-Adjusted 
 (unaudited) (1)(2)    |        |
| Cash and cash equivalents |     |                     | 5,055 |     |                       |  8,352 |
| Borrowings, non-current   |     |                     |   208 |     |                       |    208 |
| Total equity              |     |                     | 8,727 |     |                       | 12,024 |
| Total capitalization      |     |                     | 8,935 |     |                       | 12,232 |

_______________________

| (1) | The proceeds have been translated into British pounds sterling at a rate of £1.00 to $1.29138. |

| (2) | All proceeds from the sale of the securities have been reflected within Total equity for purposes of this                                          
 table. We will be required to complete an assessment of the accounting and valuation for such instruments, which may result in a portion           
 of the proceeds being classified outside of Total equity and remeasured to fair value each reporting period (if liability-classified instruments). 
 Such assessment will be completed in connection with the preparation of our consolidated financial statements for the period in which              
 the sales occur.                                                                                                                                   |

The table above does not include:

| · | 274,420,765 Ordinary Shares issuable upon the exercise of stock                                                
 options outstanding under our equity incentive plans at a weighted-average exercise price of £0.005 per share; |

| · | 99 Ordinary Shares issuable upon the exercise of stock options assumed in connection with the acquisition 
 of DARA Biosciences, Inc., at a weighted average exercise price of $877.13 per share;                     |

| · | warrants, including pre-funded warrants and shares held in abeyance upon exercise of warrants,                                         
 exercisable for 443,997 Depositary Shares (representing 4,439,970,000 Ordinary Shares), at a weighted-average exercise